William Kaelin, Peter Ratcliffe, and Gregg Semenza have jointly won the 2019 Nobel Prize "for their discoveries of how cells sense oxygen," the Nobel Assembly at Karolinska Institutet announced today.
William Kaelin, Peter Ratcliffe and Gregg Semenza have jointly won the 2019 Nobel Prize "for their discoveries of how cells sense oxygen," the Nobel Assembly at Karolinska Institutet announced Monday.
The leucine-repeat rich kinase 2 (Lrrk2) gets most of its attention in the context of Parkinson's disease (PD). Variants in Lrrk2 are a major cause of familial PD (though familial PD makes up only a small fraction of overall PD cases).
Researchers at Princeton University have used a combination of artificial intelligence and synthetic biology to identify and produce biologically active small molecules produced by members of the human microbiome.
At the 2019 Congress of the European Society of Medical Oncology, PARP inhibitors continued their victory march. With the success of the PAOLA-1 trial, reported in Friday's plenary session, as well as the PRIMA and VELIA/GOG-3005 trials, "we've got new front-line data that really introduces a paradigm shift into the way we're going to treat ovarian cancer in the coming years," Jonathan Ledermann, professor of medical oncology at University College London, told the audience at a session on new options on ovarian cancer.
BARCELONA, Spain – At the 2019 Conference of the European Society of Medical Oncology (ESMO), results from the ClarIDHy and FIGHT-202 trials, both testing drugs for the treatment of cholangiocarcinoma, illustrated how molecular medicine can bring new treatments to rare tumors.
BARCELONA, Spain – Sunday's Presidential Symposium at the 2019 Congress of the European Society of Medical Oncology was devoted to breast cancer studies, and two of those studies – MONARCH-2 and MONALEESA-3 – reported an overall survival (OS) benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive (HR+) breast cancer in several different settings.
Despite the fact that antidepressants are taken by more than 10% of the U.S. population, large randomized controlled trials have found little evidence that they are beneficial. However, anecdotal evidence suggests that some patients benefit strongly.
BARCELONA, Spain – This year's theme at the European Society for Medical Oncology's (ESMO) 2019 annual meeting is "translating science into better patient care."
The leucine-repeat rich kinase 2 (Lrrk2) gets most of its attention in the context of Parkinson's disease (PD). Variants in Lrrk2 are a major cause of familial PD (though familial PD makes up only a small fraction of overall PD cases).
